Research programme: cancer and antiviral therapeutics - Syntonix

Drug Profile

Research programme: cancer and antiviral therapeutics - Syntonix

Alternative Names: Interferon-α-Fc; T20-Fc

Latest Information Update: 25 Feb 2008

Price : $50

At a glance

  • Originator Syntonix Pharmaceuticals
  • Class Interferons
  • Mechanism of Action HIV fusion inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Hepatitis C; HIV infections

Most Recent Events

  • 01 Feb 2007 Syntonix Pharmaceuticals has been acquired by Biogen Idec
  • 23 Aug 2004 Preclinical trials in Cancer in USA (unspecified route)
  • 23 Aug 2004 Preclinical trials in Hepatitis C treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top